Illumina Buys Fluent BioSciences To Gain Stronger Foothold In Single-Cell Analysis
Illumina Buys Fluent BioSciences To Gain Stronger Foothold In Single-Cell Analysis
Last month, Illumina Inc (NASDAQ:ILMN) had to let go of Grail Inc. Still, the DNA sequencing company has acquired Fluent BioSciences to expand its reach in single-cell analysis and multiomics research.
上个月，Illumina公司（纳斯达克代码为ILMN）不得不放弃Grail公司。然而，这家DNA测序公司已经收购了Fluent BioSciences以扩大其在单细胞分析和多组学研究方面的影响力。
Launched in 2018, Fluent was backed by Illumina's venture capital arm. Other investors include Samsara Biocapital, Civilization Ventures, Co-win Ventures and VC23.
Fluent于2018年推出，并得到了Illumina的创投支持。其他投资者包括Samsara Biocapital、Civilization Ventures、Co-win Ventures和VC23。
While the financial details were not disclosed, the company said the deal was closed and funded with cash it had on hand.
虽然财务细节并未披露，但公司表示这笔交易已经完成，并用手头现金进行了融资。
At the close of the first quarter, the company held $1.115 billion in cash, cash equivalents and short-term investments.
在第一季度结束时，公司持有11.15亿美元的现金、现金等价物和短期投资。
Fluent's single-cell analysis technology eliminates the need for complex, expensive instrumentation and microfluidic consumables.
Fluent的单细胞分析技术消除了复杂、昂贵的仪器和微流控消耗品的需求。
Related: Gene Sequencing Firm Illumina Escapes Carl Icahn's Second Proxy Battle Amid Grail Divestment Efforts.
相关内容：基因测序公司Illumina在Grail出售努力中成功逃过Carl Icahn的第二次代理战争。
Fluent's latest release, PIPseq V, enables the detection of cell types often missed with current methods and the highest scalability, capable of processing a range from 100 cells up to 1 million.
Fluent的最新版本PIPseq V，能够检测常被现有方法遗漏的细胞类型，并具有最高可扩展性，能够处理从100个细胞到100万个细胞的区间。
The Fluent team will join Illumina, and PIPseq V will be integrated into Illumina's product portfolio. The company plans to build on Fluent's technology to develop full end-to-end solutions for single-cell analysis.
Fluent团队将加入Illumina，并将PIPseq V集成到Illumina的产品组合中。该公司计划基于Fluent的技术开发全面的单细胞分析端到端解决方案。
"The addition of Fluent BioSciences to Illumina will provide significant and new capabilities to our customers in a key growth area and advances our multiomics growth strategy," said Steven Barnard, chief technology officer of Illumina. "Single-cell research opens doors to new areas of discovery, and Fluent's innovative, accessible, and flexible single-cell method will accelerate our ability to deliver full multiomics solutions for our customers."
Illumina的首席技术官Steven Barnard表示：“Fluent BioSciences加入Illumina将为我们的客户在关键增长领域提供重要且新颖的能力，并推进我们的多组学增长策略。单细胞研究开启了发现新领域的大门，Fluent的创新、易于使用和灵活的单细胞方法将加速我们为客户提供全面的多组学解决方案的能力。”
Analyst Reaction:
分析师反应：
- Citigroup upgrades Illumina from Neutral to Buy, with a price target of $140.
- Stephens reiterates Illumina with an Overweight and maintains a price target of $170.
- 花旗集团将Illumina从中立评级调升为买入，目标价为140美元。
- Stephens重申对Illumina的超配评级，并保持170美元的目标价。
Price Action: ILMN shares are up 5.68% at $112.73 at last check Wednesday.
价格行动：截至上周三最后一次查询，ILMN股价上涨5.68%，至112.73美元。
Photo via Shutterstock
图片来自shutterstock。
- Once Valued At Around $7B, Cancer Blood Test Developer Grail To Kickstart Trading On NASDAQ.
- 曾被估值约为70亿美元的癌症血液检测开发商Grail即将开始在纳斯达克交易。